Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent development of BTK-based dual inhibitors in the treatment of cancers
Fansheng Ran, Yun Liu, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114232-114232
Closed Access | Times Cited: 19

Showing 19 citing articles:

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
Jingyu Zhang, Jinxin Che, Xiaomin Luo, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 9096-9125
Closed Access | Times Cited: 40
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 34
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database
Xiaolu Chen, Biao Zhang, Yajiao Huang, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Applications of oxetanes in drug discovery and medicinal chemistry
G. Huang, Devon G. Hucek, Tomasz Cierpicki, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115802-115802
Open Access | Times Cited: 9
Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances
Lauren Schaff, Lakshmi Nayak, Christian Grommes
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 7, pp. 882-894
Open Access | Times Cited: 1
Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation
Maoxu Xiao, Meiqi Zhu, Shuangjie Wu, et al.
Bioorganic Chemistry (2022) Vol. 130, pp. 106263-106263
Closed Access | Times Cited: 8
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma
Himangshu Sonowal, William G. Rice, Stephen B. Howell
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0277003-e0277003
Open Access | Times Cited: 4
Quantification of orelabrutinib in human plasma and cerebrospinal fluid by liquid chromatography tandem mass spectrometry
Shengnan Ji, Xiaomeng Liu, Jing Ha, et al.
Journal of Chromatography B (2023) Vol. 1221, pp. 123680-123680
Closed Access | Times Cited: 4
Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia
Fansheng Ran, Yun Liu, Jian Zhu, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106479-106479
Closed Access | Times Cited: 3
A prediction model for severe hematological toxicity of BTK inhibitors
Dan Jiang, Zaiwei Song, Peng Liu, et al.
Annals of Hematology (2023) Vol. 102, Iss. 10, pp. 2765-2777
Closed Access | Times Cited: 3
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects
Fansheng Ran, Xudong Xie, Qilin Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114913-114913
Closed Access | Times Cited: 5
Trends and hotspots for European Journal of Medicinal Chemistry: A bibliometric study
Heng Zhang, Yunfan Gao, Guangcheng Fu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115041-115041
Closed Access | Times Cited: 5
Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition
Kavindra Nath, Pradeep Kumar Gupta, Johnvesly Basappa, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Targeted small molecule therapy and inhibitors for lymphoma
Zhonghui Wang, Xiang Zheng, Guo‐Wu Rao, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 14, pp. 1465-1484
Closed Access
Advances in the treatment of mantle cell lymphoma with BTK inhibitors
Jiwei Shen, Jiawei Li, Rui Yang, et al.
Leukemia Research (2024) Vol. 147, pp. 107615-107615
Closed Access
Identification of a coagulation-related gene signature for predicting prognosis in recurrent glioma
Ming Cao, Wenwen Zhang, Jie Chen, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Emerging Role of Functional Magnetic Resonance Spectroscopy (MRS) to Monitor Response to Kinase Inhibitors in Cancer
Mariusz Wasik
Advances in Cancer Research & Clinical Imaging (2024) Vol. 4, Iss. 3
Open Access
Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma
Dan Jiang, Zaiwei Song, Yi Ma, et al.
Analytical and Bioanalytical Chemistry (2024)
Closed Access
Novel 1,3,4-trisubstituted Pyrazolopyrimidine Derivatives Show Potent Antiproliferative Activity in Mantle Cell Lymphoma
Fansheng Ran, Lun Dong, Yang Liu, et al.
Letters in Drug Design & Discovery (2023) Vol. 21, Iss. 11, pp. 2063-2071
Closed Access
Novel BTK Inhibitors for Treating Autoimmune Disorders and Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 5, pp. 759-760
Open Access
Page 1

Scroll to top